Rare diseases
Investigational molecules
Locations
Brueckenstrasse 42, 47574 Goch, Germany
medicoKIT GmbH in Goch, Germany specialises in clinical trials of conditions such as Irritable bowel syndrome, Pharyngitis, Influenza, Influenza immunisation, and other specialisations. This site conducts important research.
At medicoKIT GmbH researchers are evaluating new strategies to reduce heart‑related risk, focusing on innovative therapies and outcome measures in patients with established vascular conditions.
The site’s commercial laboratory setting enables precise biomarker analysis to support cardiovascular research in Goch, Germany.
Clinical work at the centre includes trials aimed at improving gut health, with a particular emphasis on functional bowel disorders and chronic constipation.
Advanced microbiome and herbal‑based interventions are tested using the facility’s analytical capabilities.
The laboratory conducts vaccine‑focused studies to assess the humoral immune response and long‑term safety of novel immunizations for viral illnesses.
These trials contribute to broader public‑health efforts by generating data on protective immunity in older adults.
Researchers are investigating novel analgesic approaches for patients suffering from persistent low back pain when conventional non‑opioid options have failed.
The study design emphasizes pain‑reduction outcomes and tolerability in a real‑world patient population.
Trials at the site address metabolic health, including kidney function and broader nutritional concerns linked to chronic disease.
Laboratory assays support precise evaluation of metabolic biomarkers throughout the studies.
The centre evaluates symptomatic treatments for upper‑airway infections, with a focus on rapid relief of throat discomfort.
Lozenges containing benzydamine hydrochloride and dichlorobenzyl alcohol are compared against active and placebo controls.
Studies target common respiratory conditions, assessing both antimicrobial efficacy and vaccine‑induced protection.
Outcomes include symptom scores, viral load reduction, and safety monitoring in adult participants.
The facility conducts investigations on a range of viral pathogens, seeking to improve prophylactic and therapeutic options.
Immunogenicity, durability of response, and safety are key endpoints across these viral studies.
A dedicated trial explores the potential of a botanical compound to alleviate symptoms of major depressive disorder in mildly to moderately affected adults.
The study measures changes in depression rating scales and rates of clinical remission.
Clinical trials currently enrolling participants at this site.
GermanyGermanyGermanyGermanyGermanyGermanyGermanyGermanyGermanyGermanyGermanyGermanyGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
